- Report
- March 2025
- 194 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 187 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- July 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 181 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 182 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- March 2025
- 137 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- July 2024
- 135 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 130 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- January 2025
- 226 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- February 2025
- 137 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- January 2025
- 255 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- December 2024
- 99 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Clinical Trials
- June 2024
- 80 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- June 2024
- 198 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP

Hydroxycarbamide is a drug used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by inhibiting the growth of cancer cells. It is also used to treat polycythemia vera, a rare blood disorder. Hydroxycarbamide is usually taken orally in tablet form, and is usually taken once or twice a day. It is also available in an injectable form. Common side effects of hydroxycarbamide include nausea, vomiting, diarrhea, and hair loss.
Hydroxycarbamide is a relatively new drug, and is still in the process of being approved by regulatory bodies in different countries. It is currently approved in the United States, Canada, and the European Union. It is also approved in some other countries, such as Australia, New Zealand, and South Africa.
Hydroxycarbamide is marketed by several pharmaceutical companies, including Novartis, Bristol-Myers Squibb, and Pfizer. Other companies that market hydroxycarbamide include Cipla, Teva Pharmaceuticals, and Mylan. Show Less Read more